The strong beat and raised guidance, combined with positive Phase III ReSPECT data, create a powerful catalyst. Monitor the sNDA submission timeline for REZZAYO in H2 2026 and the ongoing TPN study enrollment acceleration for further upside. The stock repurchase program and strong cash position provide downside support.
CRMD drugs
CRMD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 14 $7.93entry
- T+1 · 6mo ago −4.79%α −3.56% · $7.55
- T+5 · 6mo ago +1.64%α +2.36% · $8.06
- T+20 · 5mo ago +10.21%α +11.07% · $8.74
- T+60 · 3mo ago −5.04%α −8.63% · $7.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 diluted (30% above $0.33 consensus), driven by strong DefenCath sales ($97.5M) and the acquired Melinta portfolio ($29.9M). The company raised full-year 2026 revenue guidance to $325-345M and adjusted EBITDA guidance to $115-135M, while also announcing positive Phase III ReSPECT trial results for REZZAYO prophylaxis, supporting a bullish outlook.
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $127.4M vs consensus $105.0M (beat by 21.3%)
- GAAP diluted EPS $0.43 vs consensus $0.33 (beat by 30.3%)
- DefenCath sales $97.5M, including $9.0M favorable change in estimate
- Melinta portfolio contributed $29.9M in revenue
- Net income $38.6M vs $20.6M in Q1 2025
- Adjusted EBITDA $70.0M vs $23.6M in Q1 2025
- Raised FY 2026 revenue guidance to $325-345M (from prior $310-330M)
- Raised FY 2026 adjusted EBITDA guidance to $115-135M
- Positive Phase III ReSPECT trial for REZZAYO prophylaxis; sNDA submission expected H2 2026
- Cash and short-term investments $178.1M at quarter end
Financial Impact
Revenue beat consensus by $22.4M (21.3%); EPS beat by $0.10 (30.3%); guidance raised by $15M at midpoint
Risk Factors
- Pending TDAPA expiration could pressure DefenCath revenue in future quarters
- Non-recurring $9.0M favorable estimate adjustment inflated Q1 DefenCath sales
- Integration and operating expense growth from Melinta acquisition (opex up 139% YoY)
- Clinical trial execution risk for TPN study and REZZAYO sNDA approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294799 |
Track record
21 reports on CRMD
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers